Monopar Therapeutics (MNPR) said Sunday its ALXN1840 investigational therapy for Wilson disease showed "statistically significant neurologic improvement from baseline" in an analysis of data from three clinical trials.

The analysis also showed statistically significant psychiatric improvement from baseline, and patients who crossed over to the treatment from standard of care showed additional neurological improvement, the company said.

The analysis, which included safety data from a fourth clinical trial, showed the drug had a "favorable" safety profile, with less than 1% of patients experiencing a serious drug-related adverse event, the company said.